参考文献

［1］BERGQUIST A，VON S E.Epidemiology of cholangiocarcinoma［J］.Best Pract Res Clin Gastroenterol，2015，29（2）：221-232.

［2］BANALES J M，CARDINAL E V，CARPINO G，et al.Expert consensus document：Cholangiocarcinoma：current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma［J］.Nat Rev Gastroenterol Hepatol，2016，13（5）：261-280.

［3］TYSON G L，EL-SERAG HB.Risk factors for cholangiocarcinoma［J］.Hepatology，2011，54（1）：173-184.

［4］SAHA S K，ZHU A X，FUCHS C S，et al.Forty-year trends in cholangiocarcinoma incidence in the US：intrahepatic disease on the Rise［J］.Oncologist，2016，21（5）：594-599.

［5］VLAANDEREN J，STRIAIF K，MARTINSEN J I，et al.Cholangiocarcinoma among workers in the printing industry：Using the NOCCA database to elucidate the generalisability of a cluster report from Japan［J］.Occup Environ Med，2013，70（12）：828-830.

［6］FARIOLI A，STRAIF K，BRANDI G，et al.Occupational exposure to asbestos and risk of cholangiocarcinoma：a population-based case-control study in four Nordic countries［J］.Occup Environ Med，2018，75（3）：191-198.

［7］ISAYAMA H，TAZUMA S，KOKUDO N，et al.Clinical guidelines for primary sclerosing cholangitis 2017［J］.J Gastroenterol，2018，53（9）：1006-1034.

［8］CHALASANI N，BALUYUTA，ISMAIL A，et al.Cholangiocarcinoma in patients with primary sclerosing cholangitis：a multicenter case-control study［J］.Hepatology，2000，31（1）：7-11.

［9］LABIB P L，GOODCHILD G，PEREIRA S P.Molecular pathogenesis of cholangiocarcinoma［J］.BMC Cancer，2019，19（1）：22-26.

［10］KIM H J，KIM J S，JOO M K，et al.Hepatolithiasis and intrahepatic cholangiocarcinoma：a review［J］.World J Gastroenterol，2015，21（48）：13418-13431.

［11］KHAN S A，TAVOLARI S，BRANDIG.Cholangiocarcinoma：Epidemiology and risk factors［J］.Liver International，2019，39（S1）：19-31.

［12］CHEN M F，PERIPHRAL.Cholangiocellular carcinoma：clinical features，diagnosis and treatment［J］.J Gastroenterol Hepatol，1999，14（12）：1144-1149.

［13］LEE T Y，LEE S S，JUNG S W，et al.Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea：a case-control study［J］.Am J Gastroenterol，2008，103（7）：1716-1720.

［14］El-SERAG H B，ENGELS E A，LANDGREN O，et al.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection：A population-based study of US veterans［J］.Hepatology，2009，49（1）：116-123.

［15］PALMER W C，PATEL T.Are common factors involved in the pathogenesis of primary liver cancers？A meta-analysis of risk factors for intrahepatic cholangiocarcinoma［J］.J Hepatol，2012，57（1）：69-76.

［16］GORAL V.Cholangiocarcinoma：New Insights［J］.Asian Pac J Cancer Prev，2017，18（6）：1469-1473.

［17］SANDHU D S，SHIREA M，ROBERTS L R.Epigenetic DNA hypermethylation in cholangiocarcinoma：potential roles in pathogenesis，diagnosis and identification of treatment targets［J］.Liver Int，2008，28（1）：12-27.

［18］PENG F，JIANG J，YUU Y，et al.Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis［J］.Br J Cancer，2013，109（12）：3092-3104.

［19］WANG L J，HE C C，SUI X，et al.MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN［J］.Oncotarget，2015，6（8）：5932-5946.

［20］HONG S M，CHOI J，RYU K，et al.Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas［J］.Arch Pathol Lab Med，2006，130（1）：33-38.

［21］ZHENG T，HONG X，WANG J，et al.Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma［J］.Hepatology，2014，59（3）：935-946.

［22］BRACONIC，HUANG N，PATEL T.Micro RNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes［J］.Hepatology，2010，51（3）：881-890.